CombiGene
2,46
SEK
+3,36 %
Mindre end 1K følgere
COMBI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
+3,36%
+7,89%
+3,36%
-8,89%
-1,6%
-32,42%
-73,83%
-73,61%
-97,44%
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Læs mereMarkedsværdi
48,71 mio. SEK
Aktieomsætning
117,9 t SEK
Omsætning
330 t
EBIT %
-14.309,09 %
P/E
-
Udbytteafkast, %
-
Finanskalender
17.6
2025
Generalforsamling '25
22.8
2025
Delårsrapport Q2'25
13.2
2026
Årsrapport '25
Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Year-end report January-December 2024 CombiGene AB (Publ)
Discontinuation of research activities
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools